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In human immunodeficiency virus (HIV)-infected individuals, the proportion of circulating mononuclear
cells (PBMCs) which carry HIV provirus and the number of HIV proviral sequences per infected PBMC have
been matters for conjecture. Using a double polymerase chain reaction which allows the detection of single
molecules of provirus and a method of quantifying the provirus molecules, we have measured provirus
frequencies in infected individuals down to a level of one molecule per 10' PBMCs. As a general rule, only a
small proportion of PBMCs contain provirus (median value of samples from 12 patients, one per 8,000 cells),
and most if not all of the infected cells carry a single provirus molecule. The frequency of provirus-carrying
cells correlated positively both with the progression of the disease and with the success with which virus could
be isolated from the same patients by cocultivation methods. Of seven asymptomatic (Centers for Disease
Control stage H) patients, all but one contained one provirus molecule per 6,000 to 80,000 cells; of five Centers
for Disease Control stage IV patients, all but one contained one provirus molecule per 700 to 3,300 cells. When
considered in conjunction with estimates of the frequency of PBMCs that express viral RNA, our results suggest
that either (i) the majority of provirus-containing cells are monocytes or (ii) most provirus-containing
lymphocytes are transcriptionally inactive. We also present nucleotide sequence data derived directly from
provirus present in vivo which we show is not marred by the in vitro selection of potential virus variants or by
errors introduced by Taq polymerase. We argue from these data that, of the provirus present in infected
individuals, the proportion which is defective is not high in the regions sequenced.
Human immunodeficiency virus (HIV) causes a chronic
and eventually fatal disease in humans. The time course of
the disease is slow and involves the persistence of virus
infection in the face of a specific antiviral response by all
arms of the immune system. On primary infection there is an
initial viremia, which is followed rapidly by antibody pro-
duction and viral clearance (1, 5, 7). However, protective
immunity is not established, and signs of active infection
reappear after a variable period of time. Progression to the
acquired immunodeficiency syndrome (AIDS) correlates
with the reappearance of circulating viral proteins (7, 23) and
pathological evidence of extensive viral infiltration in many
parts of the body, such as brain, gut, spleen, lymph nodes,
and lungs (24, 26, 30, 31).
The mechanism by which HIV persists is unclear. It has
been proposed that the extensive sequence variation seen in
the env gene allows the virus to evade the immune response
(8, 32). Another possibility is that the virus evades the
immune system by virtue of a low level of gene expression in
some of the cells that it infects. Cells of the monocyte-
macrophage lineage are more resistant to the cytolytic effect
of HIV infection in vitro than are T4 lymphocytes (6). Cells
of the former type are considered by many investigators to
constitute the main reservoir of HIV infection and to be the
means by which viral infection is disseminated to multiple
sites in the body (11, 21, 28). In support of this view, HIV
can readily be isolated from macrophages. On the other
hand, there is also evidence that virus expression in periph-
* Corresponding author.
eral blood mononuclear cells (PBMCs) from AIDS patients
can be low or absent for long periods of time (35), and
nonexpressing T4 lymphocytes can be identified after in
vitro infection (4, 12).
Little is known about the distribution of proviral DNA in
cells of the peripheral circulation. Neither the number of
infected cells, the number of copies of provirus per cell, nor
the cell type which contributes most to the progression of the
disease are known with any certainty. Clearly, it is of
fundamental importance to establish these basic parameters
of the disease. Previous attempts to measure the prevalence
of provirus and the frequency of infected cells in PBMCs
from infected individuals have been only moderately suc-
cessful. Shaw et al. (30) detected HIV-specific sequences in
only 1 of 22 samples of DNA extracted from PBMCs of
AIDS and AIDS-related complex patients. The Southern
blotting method used in this case allowed the detection of
provirus molecules at a frequency of one per 200 or fewer
cells, suggesting that the prevalence of provirus-carrying
cells is usually lower than this. Ulrich et al. (34) titrated
PBMCs from asymptomatic HIV-infected patients before
attempts at isolation and found that the number of PBMCs
required to obtain a positive result varied widely between
individuals. One patient yielded a positive culture from only
100 cells, while most required 104 to 105 cells, and two
remained negative even when 106 cells were used. Harper et
al. (9) used in situ hybridization to measure the number of
HIV-expressing cells in PBMCs from a similar group of
symptomatic patients. Positive cells were seen in only half of
the samples tested, and in these samples their frequency was
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again very low (one cell in 104 to 105). While these estimates
are in good agreement, each poses problems of interpreta-
tion (see Discussion). In a number of published studies, the
polymerase chain reaction (PCR) has been used to detect
HIV proviral DNA sequences in PBMCs from seropositive
patients. A striking feature of the results obtained so far is
the scarcity or apparent absence of viral DNA in a propor-
tion of patients (3, 10, 13, 22). None of these reports includes
an assessment of the sensitivity of the method in terms of the
minimum number of HIV molecules required to produce a
positive signal. However, the results do suggest that the
proportion of infected cells within the PBMC population
may be extremely low in many cases.
Here we describe a modified PCR method with a sensitiv-
ity sufficient to detect a single molecule of target DNA. After
a first PCR amplification with a pair of HIV-specific primers,
a small proportion of the product was used as the template
for a second round of PCR amplification using a second set
of primers nested within the first pair. By combining this
double PCR method with a limit dilution approach, both the
proportion of infected cells and the number of molecules of
HIV provirus per cell can be accurately estimated. Results
obtained with PBMCs from 12 HIV-positive hemophiliacs
showed a wide range in the proportion of provirus-carrying
cells, with a median value of one provirus in about 8,000
cells; each infected cell carried about one copy of the
provirus. The approach described here also provides a way
to analyze sequence heterogeneity within populations of
HIV provirus which avoids the complications that arise
because of the lack of fidelity of the Taq polymerase (33) and
other artifacts associated with amplification.
MATERIALS AND METHODS
Materials. Seropositive blood samples were donated by
members of a cohort of HIV-1-infected hemophiliacs. Sam-
ples from 16 seronegative patients from a low-risk category
were used as negative controls. T4/T8-cell ratios were mea-
sured by fluorescence-activated cell sorting analysis, and T4
cells and monocytes were estimated by fluorescence micros-
copy. PBMCs were separated by centrifugation over Lym-
phopaque (Nyegaard) and washed twice with phosphate-
buffered saline.
HIV primers (Fig. 1) were synthesized by the Oswel DNA
Service, Department of Chemistry, University of Edin-
burgh, and were purified by high-performance liquid chro-
matography. Control primers corresponded to positions 9412
to 9430 (sense) and 9682 to 9664 (antisense) of the human
alpha-1-antitrypsin gene (GenBank accession no. K02212).
Virus isolation. The washed cells were suspended in RPMI
(Gibco) supplemented with 20 mM L-glutamine; 10% heat-
inactivated fetal calf serum; and 300 IU of penicillin, 0.3 mg
of streptomycin, 120 mg of sodium bicarbonate, 10 ,ug of
Polybrene, 100 U of anti-human alpha interferon (ICN
Pharmaceuticals Inc.), 150 U of recombinant interleukin-2
(Du Pont Co.), and 5 mg of phytohemagglutinin (Vector) per
ml. A similar number of cells prepared from a seronegative
donor in the same way 3 to 7 days previously was added on
the first day and at 7-day intervals thereafter. Virus produc-
tion was assayed at 3- to 4-day intervals for at least 30 days
by using a HIV-1 p24-antigen capture enzyme-linked im-
munosorbent assay (Du Pont) according to the instructions
of the manufacturer.
DNA preparation. The PBMCs were suspended in 400 RI
of lysis buffer (50 mM Tris hydrochloride [pH 8.0], 100 mM
NaCl, 50 mM EDTA, 1% sodium-n-lauroylsarcosine, 100 ,ug
gaa PRIMERS:
881:
882:
883:
990:
5'GGTACATCAGGCCATATCACC;
(A)
(A)
5'ACCGGTCTACATAGTCTC;
(TA)
(G)
(A)
5'GAGGAAGCTGCAGAATGGG;
(A)
(C)
5'GGTCCTTGTCTTATGTCCAGAATGCTG;
(T)
(C) (A)
(C) (A)
pol PRIMERS:
001: 5'CATGGGTACCAGCACACAAAGG;
004: 5'TCTACTTGTCCATGCATGGCTTC;
002: 5'GGAGGAAATGAACAAGTAGATAAATTAGTCAG;
(G)
003: 5'TCACTAGCCATTGCTCTCCAATT;
sense; 1214
HIV-MAL
HIV-RF
anti-sense; 1669
HIV-MAL
HIV-PV22
HIV-SF2
sense; 1407
HIV-ELI
HIV-MAL
anti-sense; 1646
HIV-CDC41
HIV-ELI
HIV-MAL
sense; 4149
anti-sense; 4380
sense; 4175
HIV-RF
anti-sense; 4290
env PRIMERS:
401: 5'GAGGATATAATCAGTTTATGG; sense; 6539
(G) HIV-CDC42
404: 5'AATTCCATGTGTACATTGTACTG; anti-sense; 6976
402: 5'GATCAAAGCCTAAAGCCATG; sense; 6560
(A) HIV-ELI
(A) HIV-MAL
(A) HIV-WMJ22
403: 5'CAATAATGTATGGGAATTGG; anti-sense; 6876
(G) HIV-MN
FIG. 1. Primer sequences and coordinates. The coordinates
listed are from HIV HXB2 (GenBank accession number K03455).
Mismatches between the primer sequences and 10 (gag) or 9 (pol
and env) published HIV-1 sequences are indicated in parentheses.
of proteinase K per ml) and incubated at 65°C for 2 h. The
DNA was mechanically sheared by pipetting it up and down
30 times through a 1-ml Eppendorf tip, extracted twice with
equal volumes of phenol and once with chloroform, and
precipitated with 1 ml of ethanol. RNA was not routinely
removed during preparation of DNA, since it is a minor
component (20 to 25%) of the total nucleic acids in mono-
nuclear cells in vivo (14, 16) and would not significantly
affect the quantification of HIV provirus. After centrifuga-
tion, the nucleic acid pellet was suspended in TE buffer (10
mM Tris hydrochloride [pH 7.5], 1 mM EDTA) and esti-
mated spectrophotometrically. All dilutions ofDNA for PCR
were made in a solution of 100 ,ug of sheared herring sperm
DNA per ml.
Dilution of cells and DNA minipreparations. The concen-
tration of PBMCs was measured with a hemocytometer, and
cells were diluted appropriately in phosphate-buffered sa-
line. DNA was prepared essentially as described above,
except that the lysis buffer was supplemented with 2 ,ug of
carrier herring sperm DNA. The pellet centrifuged out of
ethanol was dried, 20 ,ul of distilled water was added, and the
tube was heated to 95°C for 7 min. The entire sample was
then used as template for a single PCR reaction in a total
volume of 70 to 100 RI. By extracting both carrier DNA and
known amounts of cells in the same way, the overall
efficiency of the method was found to be 60 to 75%.
Double PCR method. The template DNA was present in 25
to 100 ,lI of 67 mM Tris hydrochloride (pH 8.8), 16.7 mM
ammonium sulfate, 6.7 mM MgCl2, 10 mM 2-mercaptoeth-
anol, 6.7 puM EDTA, 33 ,uM each of dATP, dCTP, dGTP,
and TTP, 170 pRg of bovine serum albumin per ml, 10%
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dimethylsulfoxide, 0.5 ,uM of each of the outer nested
primers, and 0.015 U of Taq polymerase (Cetus) per ,ul.
Twenty-five heat cycles were used, with each consisting of
0.6 min at 94°C, 0.7 min at 50°C, and 3 min at 68°C. Two
microliters of the reaction mixture was then transferred to a
second tube containing the same medium as before but with
the inner pair of nested primers, and a further 25 heat cycles
were carried out with the same program.
The product of the second reaction (20 ,ul) was analyzed
by means of a 3% low-melting-point agarose gel containing
ethidium bromide. The pTZ18R HaeIII markers have
lengths of 767, 458/434, 281/267, 174, 142, 137, 102, and 80
bp. The extreme sensitivity of the PCR method means that
contamination of samples by even very small amounts of
extraneous target sequence may generate false-positive re-
actions (18). This is particularly true of the more-sensitive
double PCR method. By keeping stock solutions and sam-
ples and assembling the reactions in a room from which
normal manipulation of cloned HIV sequences was ex-
cluded, potential contamination was avoided; of 40 negative-
control herring sperm DNA samples, all were negative.
Negative controls were carried through all experiments. To
act as a further negative control, all batches of samples for
DNA preparation included a negative-control sample of cells
from a seronegative donor.
In order to confirm that human DNA itself does not
generate positive results in the double PCR, DNA samples
were prepared from 36 low-risk seronegative donors. Each
was assayed in the double PCR with at least two of the three
sets of primers (env, gag, or pol). None of the samples was
positive in any assay, but all were positive after a single
control PCR (25 cycles) carried out with the alpha-i-anti-
trypsin primers.
Length variation and nucleotide sequence analysis of double
PCR products. The double PCR products obtained with
pBH1O.R3 and lambda HAT3 templates were resolved by
electrophoresis on a 5% denaturing polyacrylamide gel. The
second PCR reaction was performed with inner primers end
labeled by using polynucleotide kinase and [32P]ATP (Am-
ersham Corp.; 300 Ci/mmol). The gel was dried and exposed
to X-ray film for 1 h.
To increase the amount of product available, a triple PCR
was performed with the gag primers. The second set of
cycles was carried out with one inner (883) and one outer
(882) primer, and the third set was carried out with both
inner primers as usual. In this way, each single initial
template molecule yielded about 1 ,ug of product. The
product DNA was purified by treating the reaction mixture
with Gene-Clean (Bio 101, Inc.) and eluting with TE buffer.
Approximately 500 ng of DNA was mixed with 5 ng of
32P-labeled primer 883 in TE buffer, denatured at 95°C for 5
min, and annealed at 55°C for 15 min. Nucleotide sequencing
was carried out by using the Sequenase-2 kit (United States
Biochemicals) with [35SJdATP according to the instructions
of the manufacturer.
RESULTS
The PCR depends critically on the hybridization of the
primers to specific sequences in the target DNA, and it is
therefore important that the primers should correspond to
the most invariant regions of the genome. There is consid-
erable sequence diversity between different isolates of HIV-
1. For example, the overall identity between HIV-HXB2, a
North American isolate, and HIV-MAL, from Zaire, is
87.9%. The gag and pol genes are more highly conserved
FIG. 2. Single and double PCR with serial dilutions of pBH1O.R3
DNA. The gag primers shown in Fig. 1 were used. (A) Single PCR.
(B) Double PCR. A sample from each single PCR was run on an
agarose gel (A). Another sample was used to initiate the second
PCR, and a sample of the double PCR product was also run on the
same agarose gel (B). The quantities of template added to the first
set of PCR reactions were as follows for the respective lanes: 1, 6.5
pg; 2, 650 fg; 3, 65 fg; 4, 6.5 fg; 5, 650 ag; 6, 65 ag; 7, 6.5 ag; 8, 0.65
ag. Lane 9 contains carrier herring sperm DNA alone, and lane 10
contains DNA markers (HaeIII digest of pTZ18R). Extra bands of
higher molecular weight were seen when relatively large amounts of
template were transferred to the second reaction. Such DNA
constitutes the linear accumulation of DNA copied from an inner
primer-binding site to the end of DNA molecules bounded by the
outer primers. (C) Samples, each nominally containing 6.5 ag, were
simultaneously assayed in the double PCR. Lanes: 1, carrier DNA
(negative control); 2 through 12, nominal 6.5-ag samples; 13, 65-ag
sample; 14, markers.
than the env gene (89.3 and 90.6%, respectively, versus
85%). The nested sets of gag, pol, and env sequences that
were used in the work described here were chosen to be as
highly conserved as possible (Fig. 1).
Reliable detection of single template molecules by double
PCR. The double PCR overcomes the problem of limited
amplification of a rare template sequence. Nested primers
were used previously to amplify a single-copy human gene
(20). During the first set of cycles, occasional interactions
between the primers and mismatched sequences present in
the genomic or carrier DNA led to some amplification of
sequences other than the intended target sequence. The
internally nested second primer pair ensured that only the
desired sequences were further amplified during the second
set of cycles. To take an example, in the amplification of the
gag sequence the first step with the outer primers generated
a 455-base-pair (bp) fragment. This product is then further
amplified by using the inner primers to give a shorter
(248-bp) fragment. Other nested outer and inner primer pairs
were used in the same way. The procedure allowed the
unequivocal identification of product HIV-specific DNA by
agarose gel electrophoresis with ethidium bromide staining
(Fig. 2).
Serial 10-fold dilutions of plasmid pBH10.R3 DNA were
made in a solution of herring sperm DNA to obtain plasmid
J. VIROL.
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DNA concentrations ranging from 65 ng/ml to 65 ag/ml.
When 10-,u samples from these dilutions, containing from
6.5 ng to 0.65 ag of plasmid, were amplified with the use of
the outer gag primer pair, the lowest amount of starting
material that gave a clearly visible band of the expected size
(455 bp) was 65 fg (Fig. 2A). Addition of more Taq polymer-
ase and further heat cycling did not measurably improve the
sensitivity of the reaction (data not shown). On further
amplification with the inner gag primers, the expected
248-bp band was detected from as little as 6.5 ag of starting
material (Fig. 2B). The larger bands present in reactions
which contained greater amounts of template were probably
the result of copying DNA which was correctly amplified
during the first reaction beyond the opposite internal primer
site and on to the end of the template. Products of this type
of reaction should accumulate linearly with cycle number
rather than exponentially.
The mass of one copy of pBH10.R3, obtained by dividing
the molecular weight of the 13-kbp double-stranded DNA
molecule by Avogadro number, was 13 ag. Thus, the posi-
tive double PCR result with a nominal 6.5 ag of DNA (Fig.
2B) presumably represents a reaction which contained a
single template molecule. If so, other samples taken from the
same DNA dilution should contain no plasmid molecules. To
test this, parallel replicate assays were carried out so that
each reaction nominally contained 6.5 ag of pBH10.R3
DNA. The expectation was that plasmid molecules would be
distributed to some but not all of the replicate reactions. In
agreement with this expectation, some of the reactions gave
a positive result while others gave a negative result (Fig. 2C).
The positive reactions gave bands of similar intensity, and
the proportion of positive to negative reactions was similar
when the same set of assays was performed on separate
occasions. The negative control reactions (with 1 ,ug of
herring sperm DNA) were invariably negative.
If the results were due to the distribution of single plasmid
molecules to some but not all reaction tubes, the frequency
of positive samples can be compared with an expected
frequency calculated from the plasmid DNA concentrations.
As a first approximation, an average (positive reactions/total
reactions) could be taken. A more accurate method is to
make allowance for reactions that contain two or more
template molecules (which cannot be distinguished from
those that contain one) by using the null class of the Poisson
distribution. (The mean number of template molecules per
reaction [m] is equal to -ln[F], where F is the fraction of
negative reactions.) The corrected average may then be used
to calculate the concentration of DNA molecules in the
solution from which the samples were taken. An extensive
series of reactions carried out with appropriate dilutions of
pBH10.R3 DNA produced positive reactions at 78% of the
frequency predicted (data not shown).
Separate amplification of individual molecules from a mix-
ture after dilution and distribution. If the double PCR can
detect single DNA molecules, then it should be possible to
separate single molecules of two types from a mixture of the
two by dilution and distribution and to amplify them sepa-
rately. In order to test this proposition, a mixture was made
of two clones derived from different HIV isolates, pBH10.R3
(HIV-HTLV-IIIB) and lambda HAT 3 (HIV-RF), and the
mixture was diluted, distributed, and amplified as before by
double PCR. The two variants differed in length by 42 bp in
the sequence amplified by the env primers, so that the
products could be readily distinguished by polyacrylamide
gel electrophoresis (Fig. 3). The length of sequence between
the gag primers is the same in each case. Figure 3, lanes 2
1 5 10 15 20 25 30
v V V V V V V
a
b ~K-- - -
D
,w D- -m mw -m w 40
FIG. 3. Separate amplification of single molecules from a mix-
ture. A mixture of pBH10.R3 and lambda HAT 3 was diluted in
herring sperm DNA, and the appropriate dilutions were distributed
to 28 tubes. Each sample contained (nominally) 6.5 ag of pBH10.R3
(0.5 molecules) and 60 ag of lambda HAT 3 (1.2 molecules). Another
tube contained herring sperm DNA but no HIV sequences (negative
control), while positive controls contained 65 ag of pBH10.R3 (5
molecules) or 400 ag of lambda HAT 3 (9 molecules), also in carrier
herring sperm DNA. The first PCR contained the env and gag outer
primers. A single sample of each PCR product was then amplified
with radiolabeled inner env and gag primers. The products were run
on an acrylamide gel, which was exposed to X-ray film. The
amplified env sequences of lambda HAT 3 (a; 359 bp) and pBH10.R3
(b; 317 bp) are readily distinguishable; c (248 bp) is the amplified gag
sequence. Lanes: 1, negative control (carrier DNA); 2 and 32,
lambda HAT 3 alone; 3 and 33, pBH10.R3 alone; 4 to 31, the 28
samples distributed from the diluted mixture. Longer gag sequences
are present in some samples (between bands marked b and c) for the
reasons outlined in the legend to Fig. 2.
and 32 show the results of amplifying lambda HAT 3 alone,
and lanes 3 and 33 show the results of amplifying pBH10.R3
alone. After dilution of the mixture of the two sequences
(lanes 4 through 31), a clear separation of pBH10.R3 and
lambda HAT 3 env sequences was seen. Of 28 reactions, 9
showed amplification of the pBH10.R3 env sequence (cor-
rected mean, 0.39 molecules per reaction), while 13 of 28
reactions showed amplification of the lambda HAT 3 env
sequence (corrected mean, 0.62 molecules per reaction). The
number of reactions in which the amplification of both env
sequences was expected to occur, calculated from these
numbers with the assumption of independent distribution,
was four. The observed number of three is in good agree-
ment with expectation.
The results obtained with the gag and env primers were
not in complete agreement. In S of the 28 replicates, either
the gag or an env sequence was amplified, but not both. This
is probably due to breakage of the molecules during the
serial dilution. Note that the breakage of molecules did not
affect the accuracy of the dilution method in estimating
amounts of HIV provirus, except in the presumably rare
event of breakage within the sequence to be amplified.
Low levels of HIV provirus in circulating PBMCs of HIV-
positive patients. PBMC DNA was prepared from 52 blood
samples obtained from 28 HIV antibody-positive patients
and assayed in the double PCR reaction with gag, pol, and
env primers (Fig. 1). In these screening experiments, 1-,ug
samples of genomic DNA were used. All but one of the
samples were positive for all three primer sets. A positive
result was later obtained with the initially negative sample
(RVL1; see below). Uniformly negative results were ob-
tained with single PBMC DNA samples from each of 48
low-risk seronegative blood donors. Clearly negative results
were also obtained on testing 5- and 10-,ug samples of
negative blood donor DNA in the double PCR.
On the assumption that buffy coat cells are diploid (6.6 pg
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TABLE 1. Titration of HIV proviral DNA in DNA from PBMCs
of HIV-positive individuals by dilution, distribution,
and double PCR amplification
(No. of positive reactions)/(no. of reactions tested)
Patient at a DNA dilution (in 103 cell equivalents) of a:
no.
500 100 50 25 13 10 5 2.5 2.0 1.0 0.5 0.25 0.13
74 1/1 V1 1/1 5/13 1/3 0/3
75 1/1 4/6 2/8 0/1
76 4/4 3/7 4/16 0/1
77 1/1 2/2 4/4 7/11 0/5
78 1/1 6/11 0/1
79 5/5 1/1 3/3 8/9 1/4 1/3 3/11 0/1
80 1/1 4/6 5/13 0/1
82 2/2 2/2 5/5 4/5 8/17
83 3/3 2/3 4/8 0/4
84 3/3 3/3 4/8 6/12 0/5
85 3/3 3/3 5/5 5/5 1/4 0/4
86 3/3 4/7 0/8
a DNA was extracted from at least 106 cells in each case, and cell
equivalence was calculated on the basis of a DNA content of 6.6 pg per cell.
The dilutions shown were tested in the double PCR. Blank spaces signify that
no tests were made at those dilutions.
per cell) and in the Gl phase of the mitotic cycle, 1 p,g of
DNA corresponded to 150,000 cells. In order to quantify the
amount of provirus, 12 of the DNA samples were assayed by
amplification after dilution and distribution (Table 1). These
were a random sample to the extent that they were the first
12 fresh blood samples from different patients to become
available. In each case, some of the selected dilutions gave
both positive and negative reactions. The frequencies with
which negative reactions occurred at appropriate dilutions
were used to estimate the number of molecules of HIV-
specific DNA in each sample. To allow comparison with
results obtained by titrating cells (described below), amounts
of DNA were expressed in cell equivalents (1,000 cell
equivalents corresponds to 6.6 ng of DNA). In most cases,
relatively few replicates were tested at the limiting dilutions,
and the estimates are therefore subject to a degree of
uncertainty. However, the amount of virus present in mate-
rial from different patients clearly varies greatly, ranging
from 12 copies per 106 cells (patient 76) to 1,360 copies per
106 cells (patient 82) (Table 2; reciprocals of values listed in
column 2). There is a strong positive relationship between
the success of virus isolation from a patient over the previ-
ous year and the amount of HIV provirus detected by the
PCR (Table 2, columns 1 and 2); according to the Spearman
coefficient of rank correlation, the probability of the ob-
served association occurring by chance is <0.02. No rela-
tionship was evident between the number of provirus mole-
cules and the proportion of either T4 cells or monocytes
present (Table 2, columns 4 and 5). This discounts the
possibility that the variation in the number of target cells
accounts for the variation in the amount of provirus. Finally,
a positive association existed between disease status and
amount of provirus (Table 2, column 6); samples from
patients with AIDS or AIDS-related complex (Centers for
Disease Control [CDC] categories IVc and IVa) usually
contained greater amounts of provirus than samples from
asymptomatic patients, although this association was not
statistically significant (P = 0.2). Thus, the likely explana-
tion of the reported association between isolation rate and
disease state (2, 17, 27) is a dependence of both on the
frequency of provirus.
The negative sample (RVL1; see above) was the only
sample obtained from one of the patients. Three 5-,ug por-
TABLE 2. Comparison of amount of HIV provirus with success
of virus isolation and disease status
No. of Success %CD4+ %
Patient cells per of isola- lympho- Mono- CDC stage
no. single tionb cytes in cytes in (clinical status)
provirusa PBMCs PBMCs
76 83,000 0/2 11 24 IIC
80 50,000 NDd 17 9 II (weight loss)
75 30,000 0/6 29 20 IVa, IVc (renal tuber-
culosis)
78 30,000 0/1 20 33 II
83 14,000 0/2 24 14 II
84 10,000 0/3 17 22 II
86 5,800 ND 12 16 II
79 3,300 2/4 21 14 IVc (oral candida in-
fection)
77 2,500 1/2 8 28 IVa (for 2 yrs; on 3'-
azido-3'-deoxythy-
midine)
74 2,000 4/4 10 13 IVa, IVc (oral candida
infection)
85 900 2/4 12 16 IVc (oral candida in-
fection)
82 700 2/2 21 13 II
a Number of PBMCs calculated to contain a single molecule of provirus;
derived from data shown in Table 1.
b Results obtained over the preceding year ([number of cultures which
became positive for p24 antigen]/[number of cultures tested]).
c II, Asymptomatic.
d ND, Not determined.
tions of this sample were positive in the double PCR, and
when 13 1-,ug portions of this sample were assayed, 7 were
positive (data not shown). Thus, all of the samples from
seropositive patients that we have examined were positive
either in the initial screen or on closer examination. The 7 of
13 positive samples indicate that the sample from patient
RVL1 had five provirus copies per 106 cells.
Low copy number of HIV provirus in infected cells. Be-
cause the number of copies of HIV provirus present in a
single infected PBMC in vivo is unknown, the titration of
PBMC DNA from patient material does not provide a
measure of the number of infected cells present. However,
the number of infected cells can be estimated by diluting and
distributing the cells themselves before DNA isolation. In
this case a Poisson distribution of HIV-positive cells, rather
than of DNA molecules, should occur at the limiting dilu-
tions.
This cell dilution and distribution procedure was carried
out with samples obtained from four patients. The DNA
prepared from each of the distributed samples was amplified
with the double PCR to score the samples which contained at
least one HIV provirus. From these data, the proportion of
cells which contained one or more provirus molecules was
calculated (Table 3). The values obtained ranged from one
HIV-positive cell per 16,700 cells (patient 84) to one HIV-
positive cell per 500 cells (patient 85). This corresponds to
one HIV-positive T4 cell per 2,800 (patient 84) and per 55
(patient 85) T4 cells. Similarly, if both T4 cells and mono-
cytes are infected, the calculation gives one HIV-positive
cell per 6,500 (patient 84) and per 130 (patient 85) infectable
cells.
The number of provirus molecules per cell may be calcu-
lated without reference to the proportion of infectable cells
from two measured values: (i) the proportion of all cells
which contain provirus and (ii) the proportion of DNA cell
equivalents which correspond to a single provirus molecule.
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TABLE 3. Proportion of PBMCs from HIV-positive patients
which contained HIV proviral DNA
(No. of positive reactions)/(no. of reactions No. of
tested) at a dilution (in units of 103 cells cells or cell
Patient Type of or cell equivalents) of: erusinle
no. dilution per single
molecule
13 10 5 2.5 2.0 1.0 0.5 0.25 0.13 of HIV
provirus
83 Cell 3/4 0/2 7,200
DNA 4/8 0/4 14,500
84 Cell 2/2 0/2 16,700a
DNA 4/8 6/12 0/5 10,800
85 Cell 2/2 2/2 2/2 2/2 2/2 4/6 460
DNA 3/3 3/3 5/5 5/5 1/4 0/4 870
86 Cell 3/6 2/4 10,800
DNA 3/3 4/7 0/8 5,900
a Values for 1.0 x 104 and 1.3 x 104 cells were aggregated.
In general, the titration of cells and DNA gave very similar
results, showing a similar prevalence of positive reactions at
limiting dilution (Table 3). The similarity in the two sets of
figures provides very strong evidence that in the patients
tested there is approximately one copy of provirus per
HIV-infected cell. The relatively small data sets do not
justify a more precise interpretation than this. The efficiency
of the method that was used to prepare DNA from the
diluted cells is between 60 and 75% (see Materials and
Methods). Correcting for this would only slightly increase
the predicted numbers of infected cells.
Nucleotide sequences of PCR products confirm the amplifi-
cation of single molecules. As a further confirmation that
single molecules of proviral DNA from PBMC DNA were
being detected in the double PCR, amplified DNA was
recovered from positive reactions obtained at the limiting
dilutions and sequenced. It is known that proviruses with
different nucleotide sequences may be present in a single
isolation (26). If so, and if the positive reactions were due to
the amplification of several molecules, sequence ambiguities
should be observed, with more than one base sometimes
appearing at the same position. Furthermore, differences in
sequence will in general not be observed between parallel
PCR products from the same DNA sample. On the other
hand, if the positive reactions were due to the amplification
of single molecules, each should give an unambiguous se-
quence. Also, if more than one provirus sequence was
present in a given blood sample, different sequences should
be amplified in different parallel reactions.
Limiting-dilution PCR products from patients 75, 76, and
79, amplified with gag primers, were sequenced directly by
using primer 883. In the case of patient 75, 13,000 cell
equivalents ofDNA were an,plified, in the case of patient 76,
25,000 cell equivalents were amplified, and in the case of
patient 79, 1,000 and 2,000 cell equivalents were amplified.
These dilutions gave a low frequency of positive reactions
(Table 1) and hence, if our conclusions are correct, the
probability was high that single molecules would be ampli-
fied. Each amplification product gave an unambiguous read-
able sequence of at least 175 bases. Five of the seven
sequences are unique, with variation both between samples
derived from different patients and between parallel ampli-
fication reactions originating from the same DNA prepara-
tion (Table 4). The sequence differences showed a bias
towards synonymous mutations, an indication of functional
constraints on variation in this region consistent with that
observed between published gag sequences (15). As an
TABLE 4. Variation between single provirus nucleotide
sequences derived from HIV-infected patients'
Patient Reaction Nucleotide sequence no.
no. no.b 36 69 136 165 171 183 184 201
75 C G T T G
76 a C G
b A G
c C T
79 a G T
b
c G T
a Deviations shown are from the consensus of the published sequences
shown in Fig. 1. The position indicated relates to the 5' end of the fragment,
i.e., the 5' end of the inner gag primer (Fig. 1, primer 883). Silent mutations
are in boldface type.
b Positive reactions obtained after distributing a limiting dilution.
illustration of the results obtained, Fig. 4 shows a difference
in sequence between two reactions (b and c) from the DNA
of patient 79.
Finally, a positive amplification reaction obtained from 105
cell equivalents of DNA from patient 76 was sequenced.
This larger amount of template DNA was likely to contain
several copies of provirus, and this was confirmed by the
discovery of two ambiguities in the sequence. At each of
these sites two bands of similar intensity were seen rather
than the expected single band. In summary, the absence of
ambiguities and the observed variation between and within
patient samples when limiting dilutions of PBMC DNA were
79b l79c
100-
80-
70-'1
60-
G A T C G A T C
FIG. 4. Direct nucleotide sequencing of double PCR products.
The PCR products were derived from single molecules of HIV
provirus (b and c) from patient 79. The sequence shown lies between
the inner gag primers (Fig. 1). A single nucleotide difference (A or
G, position 69) can be seen.
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amplified support the evidence cited above that the double
PCR detected single molecules of HIV provirus.
DISCUSSION
Frequency of provirus-containing cells. The PBMCs used in
these experiments were donated during 1988 and 1989 by
HIV-seropositive hemophiliacs who are believed to have
been infected in 1984 (19). Seven were asymptomatic, and
five displayed AIDS or AIDS-related complex (Table 2). The
most striking feature of the results is the extremely low level
of HIV provirus present in the circulating PBMCs in most
cases. The samples that were then used to assess how many
PBMCs carry provirus came from three asymptomatic pa-
tients and one with AIDS. The frequency of infected PBMCs
from the patient with AIDS was about 1 per 500, while from
the asymptomatic patients it was about 1 per 10,000 (Table
3). The fact that the relationship between circulating provi-
rus and infected cells in each of these samples is close to one
allows tentative extrapolation to the other eight samples.
Overall, the frequencies ranged from about 1 per 700 to 1 per
80,000 cells, with a median value of 1 per about 8,000 cells(Table 2).
Of the seven asymptomatic (CDC stage II) patients, all but
one fell into the range of 1 per 5,000 to 80,000 cells, while of
the five CDC stage IV patients, all but one fell into the range
of 1 per 700 to 5,000 cells. Thus, there is a positive
association between the frequency of infected cells and
disease status. The correlation with success of viral isolation
is stronger, although this interpretation is tempered by the
low number of isolation attempts made in some cases. Five
patients who did not yield virus isolates in a total of 14
attempts all had virus present in 1 per 10,000 or more cells,
while five from whom virus was isolated in 11 of a total of 16
attempts all had virus present in 1 per 3,000 or fewer cells.
Schnittman et al. (29) titrated DNA from PBMCs from three
patients with AIDS and reported a frequency of 1 provirus
per around 100 CD4+ positive cells. If one assumes that the
CD4+ lymphocytes are the sole reservoir of HIV provirus,
then the proportion of infected CD4+ cells in the patients
with AIDS can be compared with the figures obtained by
Schnittman et al. (29). Figures of one provirus per 100, one
per 200, one per 700, and one per 8,700 CD4+ cells were
obtained in this way for the four patients with AIDS studied
here.
The distribution of provirus frequencies among the 12
patients was similar to a distribution reported by Ulrich et al.(34). These authors attempted virus isolations from serially
diluted PBMCs from 23 asymptomatic HIV-positive pa-
tients. A total of 104 cells was sufficient for a successful
isolation in 65% of the 23 cases; for comparison, samples
from 7 of our 12 patients (60%) contained one or more
proviruses per 104 cells. Again, 105 cells were sufficient for
an isolation in 83% of the 23 cases, while samples from all(100%) of our patients contained one or more proviruses per
80,000 cells. The close correspondence of the two sets of
data seems to suggest that a single provirus-containing cell is
sufficient to initiate an isolation. However, our own attempts
to isolate virus from the same patients who donated the
samples used in the provirus analysis are at variance with
this. Our isolations were carried out with approximately 2 x
106 cells. Thus, all of our successful isolations occurred
when at least 500 infected cells were present, and failures
were invariably experienced with those samples which con-
tained fewer infected cells (Table 2). The discrepancy may
be more apparent than real. Ulrich et al. did not have
available numerical data on levels of provirus infection.
Consequently, even though their patients were asympto-
matic, it is possible that they represent a subset of such
patients with high levels of provirus. Other uncertainties
relate to the precise conditions under which virus was
isolated in the two laboratories.
The direct comparison with isolation rates is of interest in
relation to the numbers of PBMCs from patients with AIDS
which were observed to contain transcriptionally active
provirus (9). The more usual frequency was in the region of
one per 105 cells, ranging up to one per 104 cells, while in
50% of the samples no cells containing viral RNA transcripts
were observed. This must represent a frequency at least two
orders of magnitude lower than that of provirus-containing
cells in the patients with AIDS studied by us. Thus, it is
possible that only a minority of infected cells are transcrip-
tionally active and that only the same minority are capable of
initiating an isolation. This view, which was previously
proposed in part by Richman et al. (25), could presumably be
tested by careful quantitation of provirally infected and
actively transcribing cells within the same samples.
Two explanations of the low frequency of transcriptionally
active cells may be considered. (i) The greater part of the
provirus-containing cells are monocytes, which may exhibit
lower rates of HIV transcription than lymphocytes (11, 21,
27). (ii) Most lymphocytes which contain provirus are tran-
scriptionally silent or nearly so, a situation observed in vitro
by Folks et al. (4). These explanations are not mutually
exclusive. It should be possible to resolve the question fully
by carrying out experiments similar to those reported here
with sorted cell types.
If most lymphocytes which contain provirus are transcrip-
tionally silent, it might be because the provirus that they
carry is defective. We have some evidence bearing on this.
Using the dilution, distribution, and double PCR method to
amplify single sequences, we have determined a 180-bp
sequence from the gag region of 19 single provirus molecules
from six patients who were probably infected with the same
virus (19) (7 of these are illustrated in Table 4). Among the
sequences, there are 16 variable sites, i.e., sites at which one
or more of the sequences differs from the consensus of all of
them. None of these differences introduced either a stop
codon or a frameshift (unpublished data). Similarly, analysis
of a 170-bp sequence from the env region of 24 single
molecules from four patients revealed 49 variable sites and a
minimum of eight independent deletions or insertions.
Again, no stop codons or frameshifts were found, and the
deletions or insertions all involved a multiple of three
nucleotides (P.S. and P.B., unpublished results). The total
length of sequence considered here is approximately equiv-
alent to one HIV genome. If the regions that were sequenced
are typical, we may effectively exclude the possibility that
most of the observed provirus is defective because of
random mutational events.
These observations argue against the presence of a large
proportion of inactive provirus in the PBMCs, but only with
the assumption that the sites of inactivation are distributed
through the genome at random. If instead they are confined
to particular regions, such as the regulatory regions of the
genome (tat, rev, nef, and the long terminal repeat), we
would not have detected them in the course of this analysis.
Also, gross disruptive rearrangements of the proviral DNA
would usually not be detected by the PCR.
The possibility that much of the provirus population may
be transcriptionally inactive is supported by the finding of
latency after in vitro infection (4, 35). Even if only a small
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proportion of ongoing virus production produces a latent
infection in vivo, the proportion of latently infected cells
may steadily increase as the infection progresses, since the
cells infected with active virus are probably destroyed.
Provirus may be integrated into the chromosome at a site at
which its expression is prevented, or it may be transcription-
ally inactive by virtue of being extrachromosomal. The
question of proviral inactivation is currently under investi-
gation.
Sequence variation in HIV. The analysis of nucleotide
sequence variation in HIV has presented serious difficulties.
It is difficult to isolate molecular clones of provirus directly
from PBMCs because of the low ratio of provirus genomes to
cellular genomes. Once virus has been isolated by in vitro
propagation, which increases the proportion of infected
cells, provirus may be more readily cloned. However, the in
vitro propagation of virus introduces new uncertainties.
Selection of variants which grow more successfully in vitro
may occur, or inviable variants which are sustained by
complementation or phenotypic mixing in multiply infected
cells may accumulate. Thus, viral sequences isolated after in
vitro propagation may not be truly representative of the viral
sequences present in the donor.
Another approach is to amplify the proviral sequences
which are present in DNA extracted from PBMCs by the
PCR method and to isolate molecular clones of the amplified
product for sequencing. This method is also liable to give
misleading results. The Taq polymerase introduces an error
in about 1 nucleotide in 9,000 (33). This means, for example,
that after 20 cycles of amplification, 20% of 200-bp strands
and 68% of 1-kilobase strands will carry one or more errors.
(The proportion of strands with no errors is {1 - (L12E)}N,
where L is the effective length of the template in base pairs,
E is the reciprocal error rate per nucleotide, and N is the
number of cycles.) Thus, it will be difficult or impossible to
decide, after cloning and sequencing single amplified mole-
cules, which differences are original and which were intro-
duced by the polymerase. The dilution and distribution
method which we have described here overcomes all of
these difficulties. Only if an error occurs in the first cycle of
amplification is it likely to cause a problem of interpretation.
In this case, the error affects one-quarter of the fully
amplified product; errors that occur during the second and
subsequent cycles affect progressively less of the product.
First-cycle errors will occur only rarely, during 1 in 10
amplifications of a 500-bp sequence or 1 in 25 amplifications
of a 200-bp sequence. Such errors will be detected as
ambiguities. The frequency of reactions which show a se-
quencing ambiguity because more than one template mole-
cule is present will usually be greater than this. From the
Poisson distribution, when 50% of reactions are positive,
about one-third of the positive reactions will contain two
template molecules; when 25% are positive, about one-
eighth of the positive reactions will contain two templates.
The best practice would seem to be to disregard all reactions
in which sequence ambiguities arise.
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